Cytek Biosciences, Inc.

Annual Trend FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Cash flows from operating activities:
Adjustments to reconcile net income to net cash provided by operating activities:
Net Income (Loss) Attributable to Parent $19.4m $3.0m $2.5m ($12.1m) ($6.0m) ($66.5m)
Net Income (Loss) Available to Common Stockholders, Basic $3.2m $0 $2.6m ($12.1m) ($6.0m) ($66.5m)
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest $19.4m $3.0m $2.5m ($12.1m) ($6.0m) ($66.5m)
Net Income (Loss) Attributable to Noncontrolling Interest $26k $92k $0 $0 $0
Depreciation, Depletion and Amortization $603k $1.2m $2.5m $6.0m $7.2m $7.6m
Amortization of Intangible Assets $71k $334k $835k $3.3m $3.7m $3.7m
Depreciation $532k $908k $1.7m $2.8m $3.5m $3.9m
Deferred Income Tax Expense (Benefit) ($7.4m) ($1.8m) ($11.3m) ($10.0m) ($2.9m) $33.6m
Share-based Payment Arrangement, Noncash Expense $611k $6.6m $16.6m $22.0m $26.8m $24.6m
Share-based Payment Arrangement, Expense $611k $6.6m $16.6m $22.0m $26.8m $24.6m
Gain (Loss) on Disposition of Property Plant Equipment $0 $0 ($7k) ($55k) ($415k)
Income Tax Expense (Benefit) ($5.0m) $2.9m ($1.2m) ($3.6m) $320k $36.7m
Interest Expense Nonoperating ($5.2m) $474k
Other Nonoperating Income (Expense) $994k ($1.5m) $1.0m $7.8m $4.5m $8.8m
Changes in operating assets and liabilities:
Additional Financial Items
Increase (Decrease) in Accounts Receivable $334k $12.4m $19.7m $7.3m $5.4m ($368k)
Increase (Decrease) in Inventories $5.7m $7.1m $17.7m ($4.3m) ($14.8m) $5.2m
Increase (Decrease) in Accounts Payable ($55k) ($256k) $1.9m ($1.8m) $2.6m $448k
Equity Securities, FV-NI, Gain (Loss) $0 $40k $0 $0
Gain (Loss) Related to Litigation Settlement ($1.0m)
General and Administrative Expense $9.4m $20.8m $34.7m $44.0m $43.1m $58.9m
Goodwill $476k $10.1m $10.1m $16.2m $16.7m $16.7m
Inventory Write-down $1.6m $488k $756k $1.5m $1.6m $1.7m
Investment Income, Interest $110k $49k $4.6m $6.4m $5.1m $2.2m
Marketable Securities, Unrealized Gain (Loss) $17k ($29k) $97k $58k
Nonoperating Income (Expense) $771k ($3.2m) $3.1m $12.1m $14.8m $10.5m
Operating Expenses $38.1m $70.0m $102.8m $137.3m $131.6m $144.8m
Proceeds from Stock Options Exercised $169k $642k $1.2m $1.5m $1.0m $325k
Net Cash Provided by (Used in) Operating Activities $15.2m $4.6m ($12.2m) $5.3m $25.4m ($4.7m)
Cash flows from investing activities:
Payments to Acquire Property, Plant, and Equipment $1.5m $4.4m $9.7m $4.6m $3.5m $4.1m
Net Cash Provided by (Used in) Investing Activities ($1.5m) ($21.0m) ($55.9m) ($93.9m) ($83.0m) $10.1m
Cash flows from financing activities:
Payments for Repurchase of Common Stock $44.2m $21.6m $15.1m
Net Cash Provided by (Used in) Financing Activities $122.6m $213.6m $5.5m ($41.8m) ($15.8m) ($13.4m)
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents ($587k) $1.3m ($2.5m) ($1.4m) $4.5m $109k
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $135.6m $198.5m ($65.1m) ($131.9m) ($68.9m) ($7.9m)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $166.1m $364.6m $299.5m $167.6m $98.7m $90.9m
Supplemental disclosure of cash flow information:
Income Taxes Paid, Net $2.1m $2.9m $10.4m $5.3m $3.8m $2.2m